Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners

The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…

Richard Scheller Biography and Net Worth

Director of ORIC Pharmaceuticals

Richard H. Scheller holds the position of Chairman at DiCE Therapeutics, Inc, Chairman for DICE Molecules SV, Inc. (a subsidiary of DiCE Therapeutics, Inc) and Director, Chairman-Research & Development at BridgeBio Pharma, Inc., Director, Chairman-Research & Development at BridgeBio Pharma LLC (a subsidiary of BridgeBio Pharma, Inc.). Richard H. Scheller is also Member of National Academy of Sciences, Member of American Academy of Arts & Sciences and Member of National Academy of Medicine of United States and on the board of 10 other companies.

He previously was Head-Genentech Research & Early Development at Roche Holding AG and Executive VP-Research & Early Development at Genentech, Inc. (a subsidiary of Roche Holding AG), Director & Chief Scientific Officer at Medrio, Inc. and Associate Professor at Stanford University.

He received a doctorate from California Institute of Technology, a doctorate from The Trustees of Columbia University in The City of New York and an undergraduate degree from the University of Wisconsin.

What is Richard H. Scheller's net worth?: The estimated net worth of Richard H. Scheller is at least $71,629.50 as of May 5th, 2023. Mr. Scheller owns 8,427 shares of ORIC Pharmaceuticals stock worth more than $71,630 as of November 15th. This net worth approximation does not reflect any other investments that Mr. Scheller may own. Learn More about Richard H. Scheller's net worth.
How do I contact Richard H. Scheller?: The corporate mailing address for Mr. Scheller and other ORIC Pharmaceuticals executives is 240 E. GRAND AVE. 2ND FLOOR, SOUTH SAN FRANCISCO CA, 94080. ORIC Pharmaceuticals can also be reached via phone at 650-388-5600 and via email at [email protected]. Learn More on Richard H. Scheller's contact information.
Has Richard H. Scheller been buying or selling shares of ORIC Pharmaceuticals?: Richard H. Scheller has not been actively trading shares of ORIC Pharmaceuticals during the last quarter. Most recently, Richard H. Scheller sold 100 shares of the business's stock in a transaction on Thursday, May 13th. The shares were sold at an average price of $25.00, for a transaction totalling $2,500.00. Following the completion of the sale, the director now directly owns 49,200 shares of the company's stock, valued at $1,230,000. Learn More on Richard H. Scheller's trading history.
Who are ORIC Pharmaceuticals' active insiders?: ORIC Pharmaceuticals' insider roster includes Jacob Chacko (CEO), Carl Gordon (Director), Richard Heyman (Director), and Richard Scheller (Director). Learn More on ORIC Pharmaceuticals' active insiders.
Are insiders buying or selling shares of ORIC Pharmaceuticals?: During the last twelve months, insiders at the sold shares 3 times. They sold a total of 33,779 shares worth more than $339,287.96. The most recent insider tranaction occured on February, 6th when CEO Jacob Chacko sold 13,958 shares worth more than $169,170.96. Insiders at ORIC Pharmaceuticals own 5.6% of the company. Learn More about insider trades at ORIC Pharmaceuticals.
Information on this page was last updated on 2/6/2024.

Richard H. Scheller Insider Trading History at ORIC Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/13/2021	Sell	100	$25.00	$2,500.00	49,200
4/1/2021	Sell	200	$25.00	$5,000.00	49,800

Richard H. Scheller Buying and Selling Activity at ORIC Pharmaceuticals

ORIC Pharmaceuticals Company Overview

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Today's Range

Now: $8.50

$8.10

$9.05

50 Day Range

MA: $9.72

$8.15

$11.25

2 Week Range

Now: $8.50

$6.33

$16.65

Volume

508,297 shs

Average Volume

518,164 shs

Market Capitalization

$599.82 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.13

Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners

From Colonial Metals | Ad

Claim your FREE 2024 Gold Guide